# Kuros Biosurgery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kuros-biosurgery

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.kuros.ch
- Total disclosed funding: $12M
- Latest round: Series B (Jan 1, 2005)
- Investors on record: 6

## About

Kuros Biosurgery AG focuses on developing innovative biologic technologies designed to alleviate spine-related pain, with a primary emphasis on their flagship product, MagnetOs.Founded in 2002, Kuros Biosurgery AG is based in Zurich, Switzerland, and specializes in advanced biologic solutions for surgical applications. The company has raised a total of CHF 5 million in its most recent funding round in November 2015, which was part of a larger effort that accumulated CHF 20 million. Kuros has made five deals to date, and its products are noted for enhancing the outcomes of spinal fusion surgeries. The organization operates without any known subsidiaries or parent companies.Kuros Biosurgery specializes in innovative biologic technologies targeted at managing spine-related pain through its core product, MagnetOs. MagnetOs utilizes NeedleGrip™ surface technology to promote bone growth in soft tissues, thereby improving spinal fusion success rates. The company provides a range of formulations, including MagnetOs Easypack Putty, MagnetOs Flex Matrix, and MagnetOs Granules, serving orthopedic and neurosurgeons, hospitals, and healthcare facilities across more than 20 international markets, including the United States, Canada, and various European and Middle Eastern countries.In 2023, Kuros Biosurgery reported a revenue of CHF 37,378,709.80, with an EBITDA of CHF -11,626,556.10, primarily generated through the sale of its flagship product, MagnetOs, and its related formulations, utilizing direct transactions with healthcare providers for surgical applications.Kuros Biosurgery AG aims to introduce new product lines designed to enhance surgical outcomes and plans to expand its market presence into Asia and South America by the end of 2024. The CHF 5 million raised in November 2015 is intended to support these initiatives, focusing on product development and market entry strategies to enhance its competitive landscape. The company continues to emphasize clinical trials and partnerships to solidify its market integration.

## Funding rounds

- Series B, Jan 1, 2005, $5.3M — NeoMed, Renaissance Foundation & Management, CDC IXIS, DEFI Gestion, Vi Partners, Reference Cap AG
- Series A, Nov 6, 2002, $6.9M — NeoMed, CDC IXIS, Vi Partners

## Investors

- NeoMed (https://capitalatlas.ai/funds/neomed) — Series A, Series B
- CDC IXIS — Series A, Series B
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A, Series B
- Renaissance Foundation & Management (https://capitalatlas.ai/funds/renaissance-foundation-management) — Series B
- DEFI Gestion (https://capitalatlas.ai/funds/defi-gestion) — Series B
- Reference Cap AG — Series B